NCCN Guidelines® Insights - Central Nervous System Cancers, Version 2.2022
The NCCN Guidelines for Central Nervous System (CNS) Cancers focus on management of the following adult CNS cancers: glioma (WHO grade 1, WHO grade 2–3 oligodendroglioma [1p19q codeleted, IDH-mutant], WHO grade 2–4 IDH-mutant astrocytoma, WHO grade 4 glioblastoma), intracranial and spinal ependymomas, medulloblastoma, limited and extensive brain metastases, leptomeningeal metastases, non–AIDS-related primary CNS lymphomas, metastatic spine tumors, meningiomas, and primary spinal cord tumors. The information contained in the algorithms and principles of management sections in the NCCN Guidelines for CNS Cancers are designed to help clinicians navigate through the complex management of patients with CNS tumors. Several important principles guide surgical management and treatment with radiotherapy and systemic therapy for adults with brain tumors. The NCCN CNS Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s most recent recommendations regarding molecular proﬁling of gliomas.
This activity is designed to meet the educational needs of oncologists, nurses, pharmacists and other health care professionals who manage patients with cancer.
Upon completion of this activity, participants will be able to:
- Integrate into professional practice the updates to the NCCN Guidelines for Central Nervous System Cancers
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Central Nervous System Cancers
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
Individuals Who Provided Content Development and/or Authorship Assistance
The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.
Craig Horbinski, MD, PhD, Panel Member
Donald M. Cannon, MD, Panel Member
Mary Anne Bergman, Guidelines Coordinator, NCCN
Susan Darlow, PhD, Manager, Guidelines Information Standardization, NCCN
The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Louis Burt Nabors, MD, Panel Chair, has disclosed serving as a scientific advisor for Chimerix Inc.
Jane Portnow, MD, Panel Vice Chair, has disclosed receiving grant/research support from Agios, Inc., Bayer HealthCare, Celularity, Incyte Corporation, and Novocure; and serving as a scientific advisor for IN8bio, Inc.
Milan G. Chheda, MD, Panel Member, has disclosed receiving grant/research support from Incyte Corporation, Merck & Co., Inc., NeoImmuneTech, and Orbus Therapeutics Inc.
Matthias Holdhoff, MD, PhD, Panel Member, has disclosed serving on a data safety monitoring board for Advarra, Inc. and PAREXEL International Corporation; and receiving an honorarium from Pfizer Inc.
Seema Nagpal, MD, Panel Member, has disclosed receiving grant/research support from Agios, Inc., Berg Health, Inovio, INSIGHTEC Ltd., Novocure, and PharmAbcine; serving as a scientific advisor for KIYATEC, Inc. and Mirati Therapeutics Inc.; serving on a trial steering committee for Biocept and Novocure; and serving as a consultant for EnClear Therapies, Inc.
Vinay Puduvalli, MD, Panel Member, has disclosed receiving grant/research support from Bexion Pharmaceuticals, Inc., Karyopharm Therapeutics, Merck & Co., Inc., Radiomedix, Inc., and Samus Therapeutics, Inc.; serving as a scientific advisor for INSIGHTEC Ltd., NewBio Therapeutics, Inc., Novocure, Orbus Therapeutics Inc., and Servier Laboratories; serving as a consultant for INSIGHTEC Ltd., Novocure, Orbus Therapeutics Inc., and Servier Laboratories; and having equity interest/stock options in Amarin Pharma Inc. and Gilead Sciences, Inc.
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this journal-based CME activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-23-001-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until January 10, 2024. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation